Evidence map›Paper›PMID 39837304›Full record

ArticlePathobiology : journal of immunopathology, molecular and cellular biology2025

Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas.

Anne Kathrin Höhn, Benjamin Wolf, Mirjam Forberger, Christine E Brambs, Blake Gilks, Lien Hoang, Grit Gesine Ruth Hiller, Jessica N McAlpine, Amy Jamieson, Yvette Drew and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Vulvar Squamous Cell Carcinoma: Scientific Progress and Impacts to Pathology Practice.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anne Kathrin HöhnDivision of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.
Benjamin WolfDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology (Institute of Trier), University Hospital Leipzig, Leipzig, Germany.
Mirjam ForbergerDivision of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.
Christine E BrambsDepartment of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
Blake GilksDepartment of Anatomical Pathology, Vancouver General Hospital and the University of British Columbia, Vancouver, British Columbia, Canada.
Lien HoangDepartment of Anatomical Pathology, Vancouver General Hospital and the University of British Columbia, Vancouver, British Columbia, Canada.
Grit Gesine Ruth HillerDivision of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.
Jessica N McAlpineDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Amy JamiesonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Yvette DrewBC Cancer Vancouver and Faculty of Medicine University of British Columbia, Vancouver, British Columbia, Canada.
Lars-Christian HornDivision of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTargeted therapy with antibody-drug conjugates (ADCs) has achieved promising results in the treatment of different solid tumors. Sacituzumab-Govitecan (SG), a humanized anti-Trop2 monoclonal antibody linked with the cytotoxic topoisomerase I inhibitor SN-38, has been approved for the treatment of metastatic triple-negative breast cancer. The treatment approach with SG requires the expression of Trop2 within the tumor cells. Trop2 is overexpressed in many other cancer types, suggesting a broader therapeutic application beyond breast cancer to these ADCs. We explore expression of Trop2 vulvar squamous cell carcinomas (VSCCs) and how this relates to molecular classification.

methodsImmunohistochemical Trop2 expression was evaluated on diagnostic biopsies of VSCC using an immunoreactive score. Staining results were compared to the molecular subtype of VSCC.

resultsFifty-seven cases were included in the study. 63.2% of VSCC were p16-ve/p53abn (HPV-independent (p53abn)) molecular subtype, 29.8% p16+ve/p53wt (HPV-associated) and 1.4% p16-ve/p53wt (HPV-independent (p53wt)) tumors. All diagnostic biopsies (N = 57) showed at least a weak Trop2 expression. Moderate and strong expression was seen in 15/17 (88.2%) of the p16-ve/p53abn, 32/36 (88.8%) of the p16+ve/p53wt and 3/4 (75%) of the p16-ve/p53wt molecular subtype. Expression was significantly higher, as assessed by H score, in the HPV-associated VSCC, compared to HPV-independent.

conclusionVSCCs have high expression of Trop2 and represents a promising therapeutic target. Clinical trials exploring Trop2-directed ADCs such as SG are warranted in this rare cancer type, including in the prognostically poor HPV-independent VSCC with a TP53-mutation (p16-ve/p53abn molecular subtype). The targetable molecule, Trop2, can be easily assessed by immunohistochemistry on diagnostic biopsies from VSCC.

Indexed as

Antigens, NeoplasmBiomarkers, TumorCarcinoma, Squamous CellCell Adhesion MoleculesVulvar NeoplasmsAdultAgedAged, 80 and overFemaleHumansImmunohistochemistryMiddle AgedAntigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesTACSTD2 protein, humanAntibody-drug conjugatesMolecular subtypeTargeted therapyTrop2Vulvar squamous cell carcinoma

Identifiers

PMID39837304
PMCPMC12136508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.